Li Zhengwei, Yin Yiyu, Liu Fengli
Department of Pediatric Surgery, Xuzhou Children's Hospital, Xuzhou, Jiangsu 221002, P.R. China.
Oncol Lett. 2017 Jul;14(1):497-500. doi: 10.3892/ol.2017.6243. Epub 2017 May 24.
The presence of certain cancer-related genetic and epigenetic alterations in the tumor affects patient response to specific cancer therapies. The accurate screening of these predictive biomarkers in molecular diagnostics is important since it enables the tailoring of optimal treatment based on molecular characteristics of the tumor. We searched the electronic database PubMed for preclinical as well as clinical controlled trials reporting on various multiple predictors of glioma. It was observed clearly that multiple approaches are evolving and a few of them have also shown promising results. Depending on the type of gene alteration, a wide variety of methods may be applied in biomarker testing. Among the novel methods is next-generation sequencing (NGS) technology, enabling simultaneous detection of multiple alterations. The aim of this review is to discuss the predictive or potentially predictive genetic and epigenetic alterations of diffuse gliomas. The review concludes that NGS technology is the future and may likely replace, at least to some extent, the current routinely used methods, including FISH, IHC, and PCR-based methods, in clinical diagnostics.
肿瘤中某些与癌症相关的基因和表观遗传改变的存在会影响患者对特定癌症治疗的反应。在分子诊断中准确筛选这些预测性生物标志物很重要，因为它能够根据肿瘤的分子特征定制最佳治疗方案。我们在电子数据库PubMed中搜索了关于胶质瘤各种多重预测指标的临床前和临床对照试验。很明显可以观察到多种方法正在不断发展，其中一些也已显示出有前景的结果。根据基因改变的类型，多种方法可应用于生物标志物检测。新一代测序（NGS）技术就是其中的新方法之一，它能够同时检测多种改变。本综述的目的是讨论弥漫性胶质瘤的预测性或潜在预测性基因和表观遗传改变。该综述得出结论，NGS技术是未来的发展方向，并且在临床诊断中可能至少在一定程度上取代目前常规使用的方法，包括荧光原位杂交（FISH）、免疫组化（IHC）和基于聚合酶链反应（PCR）的方法。
